-
Product Insights
NewExosome Diagnostics Inc Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Exosome Diagnostics Inc Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Exosome Diagnostics Inc (Exosome Diagnostics) is a provider of diagnostic solutions. The company develops, designs, manufactures and markets biofluid-based molecular diagnostic tests and products for use in personalized medicine. Exosome Diagnostics’ services comprises of miRNA profiling, mRNA profiling, mutation detection, ribonucleic acid (RNA) sequencing (including full RNA seq) and custom assay development services. The company also offers disease detection,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RioDerm-001 in Diabetic Foot Ulcers
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RioDerm-001 in Diabetic Foot Ulcers report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RioDerm-001 in Diabetic Foot Ulcers Drug Details: RioDerm-001 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CDK-002 in Cutaneous Squamous Cell Carcinoma (cSCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CDK-002 in Cutaneous Squamous Cell Carcinoma (cSCC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CDK-002 in Cutaneous Squamous Cell Carcinoma (cSCC) Drug...
-
Product Insights
NewNanoSomiX Inc Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our NanoSomiX Inc Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. NanoSomiX Inc (NanoSomiX) is at the forefront in establishing an entirely new class of non-invasive testing to address the need for improved brain analytic tools for research and clinical applications using brain derived exosomes. The company is headquartered in Aliso Viejo, California, the US. GlobalData's Medical Devices company profile report, “NanoSomiX Inc Pipeline Insight and Competitive Landscape, 2023" provides information...
-
Product Insights
NewBiological Dynamics Inc Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Biological Dynamics Inc Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Biological Dynamics Inc (Biological Dynamics) operates as a molecular diagnostics company. The company’s proprietary lab-on-a-chip (LOC) platform, Verita utilizes AC electrokinetics (ACE) technology for isolation of nanoparticles and macromolecules from biofluids includes whole blood, plasma and serum. It also develops lung assay to support treatment response in for patients with non-small cell lung cancer. Biological Dynamics utilizes its platform...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Relatlimab in Recurrent Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Relatlimab in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Relatlimab in Recurrent Glioblastoma Multiforme (GBM) Drug Details: Relatlimab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RioDerm-003 in Radiodermatitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RioDerm-003 in Radiodermatitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RioDerm-003 in Radiodermatitis Drug Details: RioDerm-003 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RioDerm-004 in Fistula
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RioDerm-004 in Fistula report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RioDerm-004 in Fistula Drug Details: RioDerm004 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RioMSK-001 in Osteoarthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RioMSK-001 in Osteoarthritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RioMSK-001 in Osteoarthritis Drug Details: RioMSK-001 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RioDerm-002 in Radiation Injury
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RioDerm-002 in Radiation Injury report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RioDerm-002 in Radiation Injury Drug Details: RioDerm-002 is under development for the...